

Special Issue

Next-Generation Vaccines for Animal Infectious Diseases

Message from the Guest Editors

Vaccines play a pivotal role in safeguarding against animal infectious diseases, which not only impact global livestock production but also pose a risk to human health and security. Traditional vaccines, though effective in certain cases, face challenges in terms of safety, efficacy, and speed of deployment.

Nanovaccines offer enhanced efficacy and stability compared to traditional vaccines, owing to their precise targeting and controlled release mechanisms. These vaccines hold promise for the future, revolutionizing animal infectious disease prevention and control through improved immune response induction, broader pathogen coverage, and simplified administration protocols. This Special Issue cordially invites submissions of original research and review articles primarily focused on the preclinical and clinical development of vaccines in the field of prevention and control of animal infectious diseases, including LNP-mRNA vaccines, VLP vaccines, polymeric/inorganic nanoparticle vaccines, self-assembled protein vaccines, biomimetic nanoparticle vaccines, and so on.

Guest Editors

Dr. Yongwen Luo

Prof. Dr. Huiying Fan

Dr. Qing Wang

Deadline for manuscript submissions

31 January 2025



Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



mdpi.com/si/202727

Vaccines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2024).